Year: 2025

HERZLIYA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement, payments, and loyalty platform designed to help merchants scale their business, today announced its strategic partnership with Unipaas, the leading embedded payments provider for SaaS platforms, to deliver a fully unified card present and online payments solution for SaaS platforms in the UK. Through this collaboration, Unipaas expands its embedded payments platform to support both digital and physical environments with POS devices powered by Nayax, offering together a complete payments solution. Unipaas will integrate Nayax’s retail solutions of Nova Modu and Nova 55F mobile terminals into its AI-powered embedded payments platform, adding advanced in-person capabilities to its embedded digital payments suite. All...

MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or the “Company”), a global leader in non-lethal response and public-safety technology solutions, today announced that the Alliance Police Department (“Alliance PD”) has partnered with Wrap to purchase and deploy BolaWrap® 150 devices across the department and is expected to become the first reported municipal police department in the State of Nebraska to equip every sworn officer with an immediate non-lethal response option. We believe the deployment reflects Alliance PD’s and Chief Leavitt’s commitment to modern policing strategies that emphasize safer outcomes for both officers and the community. The program is structured as an integrated non-lethal response framework that combines equipment, training, tactics, and policy alignment rather...

New SOLO™ Micro-Modular Reactor Submissions Advance Licensing as Low-Consequence Regulatory Framework Takes Shape NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company”) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors today announced continued substantive progress in the licensing of its SOLO™ Micro-Modular Reactor (MMR) through active engagement with the U.S. Nuclear Regulatory Commission (NRC), reinforcing the company’s position at the forefront of next-generation nuclear deployment. Despite the federal government shutdown, during the last quarter of 2025, Terra Innovatum has had in excess of 10 face-to-face presentation and online meetings with the NRC in which the Company has detailed a comprehensive suite of technical and regulatory...

MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — Bombardier today confirmed the company is on track to reach its previously stated net leverage ratio target of 2.0–2.5x. With the $500 million debt redemption notice announced on December 17, which is expected to close by Feb 17, 2026, the Bombardier team will have successfully reduced its long-term debt by $5.5 billion since December 2020, generating annualized interest cost savings of more than $409 million (1). This achievement reflects Bombardier’s proactive focus on responsibly deploying capital and proactively managing its debt maturity runway—all to ensure flexibility to invest in strategic growth initiatives that will further deliver value. In parallel to this, the company has seen multiple credit-rating upgrades, having most recently reached a Ba3 rating from Moody’s and BB- from...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability: The presentation will be archived on Compass’ Events page. Investors interested in scheduling one-on-one meetings with Compass on January 14, 2026 should contact their J.P. Morgan representative. Compass will also host investor meetings as part of the LifeSci Partners Corporate Access Event, January 12 & 13, 2026 in San Francisco, CA. Interested investors should contact their LifeSci representative...

DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the “Board”) has appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany has served as a director of Beneficient and as Chairman of its independent Audit Committee since 2019. He brings decades of leadership experience in financial reporting, accounting, and corporate governance within the financial services industry. Mr. Cangany retired as a partner of Ernst & Young LLP (“EY”) in 2017 after nearly 40 years with the firm, including more than two decades as a partner. During his tenure at...

Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Brazil, Austria, the Netherlands and Sri Lanka. These agreements bring the total international coverage to 39 countries, representing a combined population of more than three billion people. “We are encouraged by the rapid expansion of LungFit PH’s international footprint over the past nine months. With access to 39 countries outside of the United States,...

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function. Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity. Phase III is expected to accelerate discovery on small-molecule candidates which may promote mitochondrial health and support muscle preservation: using an exclusive dataset on mitochondrial biogenesis, the AI prioritization focuses experimental testing on the most promising candidates, reducing the number of compounds advanced for subsequent development.NEWPORT BEACH, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — NorthStrive...

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates in January 2026. Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the planned...

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it entered into an agreement with BroadOak Capital Partners (collectively, “BroadOak”), a life-sciences-focused investment and advisory firm, to provide a $40 million credit facility comprised of three term loans, all of which will be funded on December 17, 2025. The proceeds of the facility will be used to retire the Company’s existing debt obligations and associated fees, and strengthen its balance sheet and capital structure. Comprehensive Growth...